What to Expect from FDA's Approach to Regulate Medical Software

The FDA’s emerging approach to medical software product regulation has important ramifications for patients, healthcare providers and insurers as well as product developers. So, it is critically important for companies throughout the life sciences and healthcare industries that utilize software in its products to understand the important challenges and opportunities presented by this major policy shift. This webinar will provide understanding.

Purchase using Webinar All-Access Pass
One User Unlimited access to all recorded webinars for 6 Months

Recorded Version Only

(PPT + Recorded Streaming Link)

1x Person - Unlimited viewing for 6 Months (For multiple locations contact Customer Care)
rec Recorded Link and Ref. material will be available in My Account Section
Last Recorded Date: Aug-2019

Download File Only

(PPT + Recorded Training File)

Downloadable file is for usage in one location only.
(For multiple locations contact Customer Care)
Downloadable link along with the materials will be emailed within 2 business days
Customer Care

Fax: +1-650-362-2367

Email: customercare@fdatrainingalert.com

Follow us:
Why Should You Attend:

In response to the rapid growth of digital healthcare, FDA has developed a streamlined regulatory pathway for approving medical software which is creating opportunities for life science and healthcare companies including pharma. FDA has advanced a regulatory framework called the Digital Health Pre-Certification (Pre-Cert) Program which is currently in a pilot testing phase. This approach aims to make reviews of digital health products more efficient by rewarding those companies who have been assessed and evaluated by the FDA as having a “robust” culture of quality and organizational excellence for the purposes of developing digital health products. Approved companies will be permitted to have their products reviewed in a streamlined manner, thereby reducing the review time for the products by focusing on what the product is rather than what it does. This would then be paired with real-world health analytics product performance analytics and user experience components, requiring the company to track how the product is being used and to quickly address issues.

Areas Covered in the Webinar:
  • FDA’s history in regulating medical software
  • Evolution of FDA’s regulatory framework
  • 21st Century Cures Act clarifies FDA jurisdiction
  • Software functions excluded from medical device oversight
  • Medical software as a medical device (SaMD) and software in a medical device (SiMD)
  • Overview of FDA’s Digital Health Innovation Action Plan
  • FDA’s Software Recertification Program and 2019 Test Plan
  • Summary of FDA’s new regulatory framework
  • Role of stakeholders in FDA’s revised
  • What are the FDA’s next steps
  • Key questions about FDA’s streamlined regulatory approach
  • Implications for health software industry
Who Will Benefit:

The following professionals from Life sciences companies (Pharma & Drugs; Quality Management; FDA Compliance; Medical Devices & Compliance), and Hospital & Healthcare Companies (General Healthcare; Healthcare IT & Data Security and Legal & Audits)

  • Regulatory Directors/Managers
  • Medical Software/Digital Health Company Executives & Managers
  • Medical Software Design & Specification Developers
  • Real-Time Software Performance Auditors
  • Medical Software R&D Directors & Managers
  • Business Planning Executives
  • In-house Medical Software Product Legal Counsel
  • Law Firm Counsels Specializing in FDA Policy
  • Hospital & Healthcare Risk Managers
  • Customer Support & Service Directors
Instructor Profile:
Dennis Weissman Dennis Weissman

President, Dennis Weissman and Associates LLC

Dennis Weissman is a nationally known, independent analyst, consultant, speaker and thought leader for the clinical laboratory and anatomic pathology sectors for the past three decades. He is President of Dennis Weissman & Associates, LLC, Falls Church, VA, a consultancy which provides market intelligence, business leadership, public policy insights and M&A advisory series to diagnostic and life science companies. Mr. Weissman has expertise is Medicare and healthcare reform policies and trends, laboratory and pathology payment and compliance issues as well as business and financial trends affecting the diagnostic other key health care sectors. He regularly speaks on a wide variety of healthcare topics during webinars, seminars and conferences sponsored by professional associations, medical groups and healthcare companies.

Refund Policy

Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. FDATrainingAlert would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.

Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.

If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.

We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email customercare@fdatrainingalert.com call +1-888-771-6965 (Toll Free).

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

You Recently Viewed